Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
pharmaphorum21h
When licensing deals go bad - Novo sues KBP Bio for $830m
Novo Nordisk has accused Singapore-based biotech KBP Biosciences of concealing clinical data ahead of a $1.3 billion licensing agreement between the two companies in 2023 focused on blood pressure ...
yr.no21h
Novo Mesto
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...